Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Double-blind, Parallel Group, Placebo-Controlled Study)

Next Previous
X
Search
Trial Profile

Phase 3 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Double-blind, Parallel Group, Placebo-Controlled Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Taisho Pharmaceutical

    • Most Recent Events

    • 12 Sep 2021 Results of pooled analysis of three studies JapicCTI090908, JapicCTI101191 and JapicCTI11166116 published in the Journal of Clinical Pharmacology
    • 02 Oct 2013 New trial record
    • 26 Sep 2013 Results reported at 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Taisho Pharmaceutical Holdings media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top